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Iroquois homeobox 1 (IRX1) belongs to the Iroquois homeobox family known to play an important role during
embryonic development. Interestingly, however, recent studies have suggested that IRX1 also acts as a tumor
suppressor. Here, we use homozygous knockout mutants of zebrafish to demonstrate that the IRX1 gene is a true
tumor suppressor gene and mechanism of the tumor suppression is mediated by repressing cell cycle
progression. In this study, we found that knockout of zebrafish Irx1 gene induced hyperplasia and tumorigenesis in
the multiple organs where the gene was expressed. On the other hands, overexpression of the IRX1 gene in
human tumor cell lines showed delayed cell proliferation of the tumor cells. These results suggest that the IRX1
gene is truly involved in tumor suppression. In an attempt to identify the genes regulated by the transcription factor
IRX1, we performed microarray assay using the cRNA obtained from the knockout mutants. Our result indicated
that the highest fold change of the differential genes fell into the gene category of cell cycle regulation, suggesting
that the significant canonical pathway of IRX1 in antitumorigenesis is done by regulating cell cycle. Experiment
with cell cycle blockers treated to IRX1 overexpressing tumor cells showed that the IRX1 overexpression actually
delayed the cell cycle. Furthermore, Western blot analysis with cyclin antibodies showed that IRX1 overexpression
induced decrease of cyclin production in the cancer cells. In conclusion, our in vivo and in vitro studies revealed
that IRX1 gene functionally acts as a true tumor suppressor, inhibiting tumor cell growth by regulating cell cycle.
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Iroquois homeobox (IRX) is a member of transcription factor containing
homeobox and plays an important role during embryonic development
in both vertebrates and invertebrates [1]. The IRX gene was first
discovered in Drosophila during mutagenesis screens [2], and later, the
genes were also found in other animals being clustered into two groups, A
(Irx1, Irx2, and Irx4) and B (Irx3, Irx5, and Irx6) [3–9]. Further studies
have revealed that the genes are expressed in various organs including
limb [10], gonad [11], kidney [12], heart [13], and lung [14].
Although the IRX gene family seems to play pivotal roles in
patterning and cell specification during organ development in
vertebrates, recent studies have suggested that the genes are also
involved in tumor suppression [15–18]. Several years ago, IRX1 gene
was reported to suppress gastric carcinoma, demonstrating that the
tumorigenicity was significantly reduced in nude mice subcutane-
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study showed that IRX1 was found to be frequently methylated in
head and neck squamous cell carcinoma, suggesting silencing of the
malignancy [18]. IRX2 and IRX3 gene were also suggested to be
involved in suppressing carcinogenesis [19,20].
Zebrafishmodel allows easy genetic modification at a lower cost, thus
being a valuable model for cancer biology. Homozygous knockout
strategy using the zebrafish model might provide valuable functional
analysis of the gene. TALEN andCRISPR/Cas9 technologies have been
well known for this purpose in animal models, and furthermore,
zebrafish has also been demonstrated as a powerful animal model for
phenotypic analysis of genes using the technologies [21]. Our group
previously demonstrated that TALEN technology can be efficiently
applied for functional analysis of genes in zebrafish model [22].
In zebrafish, Irx1 gene exists as a duplicated form, Irx1a and Irx1b.
Thus, in this study, we used the two different knockout strategies to
establish homozygous knockout mutants of the two zebrafish genes, and
the homozygous knockout mutants showed aberrant phenotype of
hyperplasia and tumor development in multiple organs where the genes
are expressed. This result suggests that the zebrafish Irx1 gene is also
involved in antitumorigenesis. Since the IRX1 is a transcription factor, we
conducted microarray assay to identify the genes regulated by the IRX1,
and the result suggested that the IRX1 functions in cell cycle regulation.
Further analysis revealed that the antitumorigenicity was mediated by
regulating cell cycle regulation especially at G2/M phase in bile duct
cancer cells. This study provides understanding of IRX1 gene function
and discusses potential mechanism of the gene in antitumorigenesis.Material and Method
Mutagenesis of Irx1 in Zebrafish
Zebrafish homolog of Human IRX1 (Iroquois related homeobox 1)
gene exists as a duplicated form of Irx1a (Gene bank: NC_007127.7;
mRNA: NP_997067.1) and Irx1b (Gene bank: NC_007130.7;
mRNA: NP_571898.1). For targeted mutation of these Irx1 genes in
zebrafish, each gene was separately designed to induce frameshift
mutation by using TALEN technology and CRISPR/Cas9 technology
for Irx1a and Irx1b, respectively (Figure 1). The TALEN construct
targeting the exon 1 of Irx1a gene was designed by using a software
program (TAL Effector Nucleotide Targeter 2.0: TALEN Targeter)
from the Bogdanove laboratory (https://boglab.plp.iastate.edu/node/
add/talen). Based on the program, the TALEN sequences that recognize
the exon 1 were found to be 5′-TCCCCCAGCTGGGCTACCCG- 3′
(left arm, RVD sequence: NGHDHDHDHDHDNINHHDNG
NH NH NH HD NG NI HD HD HD NH) and 5′-TCCCGG
TCGGTCGCCTCCG-3′ (right arm, RVD sequence: NG HD HD
HDNHNHNGHDNHNHNGHDNHHDHDNGHDHD
NH) (Figure 1A). Spacer sequence which is flanked by the two
TALENs was 5′-CAGTATTTAAGTGCCTCCCAGGCGGTG
TAA-3′. Both TALEN constructs were generated by using TALEN
Toolbox kit (Addgene), following the protocol provided by Feng Zhang
laboratory (reference nature protocol). After the sequence verification,
capped mRNA was produced by in vitro transcription of the plasmid
(mMESSAGE mMACHINE T7 ULTRA kit (Ambion Co.))
individually consisting of left or right arm sequences.
CRISPR/Cas9 technology was applied for Irx1b knockout mutation
by using pT7gRNA (Addgene) and pRGEN-Cas9-CMV (Toolgen).
The target site was identified fromE-crisp (www.e-crisp.org) online site,finding that the target sequence of guide RNA was 5′-CCAA
GAGCGCTACCAGAGAAA-3′, which presents on exon 2 of zebrafish
Irx1b gene (Figure 1B). The construct was then generated by following
the protocol provided by Chen laboratory. After sequence verification,
pT7-gRNA construct carrying guide RNA was linearized with BamHI,
and capped mRNA was generated by in vitro transcription using
MEGAshortscript T7 kit (Ambion Co). Cas9 mRNAwas generated by
using pRGEN-Cas9-CMV.
Establishment of Irx1-Null Zebrafish Mutants
DNA break at the identified targeted site was induced by injecting
the capped mRNA into the yolk of AB zebrafish embryos using an
MMPI-2 microinjector at single cell stage. In order to make the DNA
break of Irx1a, injection mixture was prepared by reconstituting the
left and right arm mRNAs (final concentration of each mRNA,
30 ng/ml) in Danieu's buffer mixed with 0.03% phenol red, and
injection mixture for targeting Irx1b was prepared by reconstituting
50 ng/μl of Cas9 mRNA and 150 ng/μl of gRNA in 20 mM Hepes
and 150 mM KCl buffer mixed with 0.03% phenol red. Each
injection mixture was then introduced into the one-cell AB zebrafish
embryos and raised till adulthood. The F1 progenies were obtained by
backcrossing the F0 adult zebrafish to AB wild-type zebrafish.
For screening of the germline mutation, the F1 progenies were
individually verified by sequence analysis of the PCR products
amplified from the genomic DNA isolated by tail fin clipping
method. Primer sequences used to amplify the exon1 sequences of
Irx1a were 5′-ACATCAGTTGGAGCTCAATT-3′ (forward) and
5′-TGGGAGAAAAGAGCCAGATC-3′ (reverse), and the exon2
sequences of Irx1b were 5′-GGTCGCAGTATGAGCTGAAG-3′
(forward) and 5′-TTCTCCTTTTTGAGTCTCCG-3′ (reverse).
The identified heterozygous mutant zebrafish were backcrossed
again with the AB zebrafish to produce F2 progenies. The
homozygous Irx1a-null and Irx1b-null zebrafish were then obtained
from the F3 progenies produced by inbreeding of the F2 heterozygote
progenies (Figure 1).
Animal Stocks and Embryo Care
Wile-type (AB), Irx1a−/−, and Irx1b−/− zebrafish were raised in a
standardized aquaria system (Genomic-Design Co., Daejeon, Korea)
(http://zebrafish.co.kr). The system provides continuous water flow,
biofiltration tank, constant temperature maintenance at 28.5°C, UV
sterilization, and 14-hour light and 10-hour dark cycle. We strictly
followed the Guidelines for theWelfare and Use of Animals in Cancer
Research [23].
Microarray Analysis
Total RNA was extracted from the visceral organs of 3-month-old
zebrafish of AB, Irx1a−/− and Irx1a−/−/b−/− using RNeasy Miniprep
kits (Qiagen, Valencia, CA, USA). The RNA purity and integrity
were evaluated by ND-1000 Spectrophotometer (NanoDrop,
Wilmington, USA) and Agilent 2100 Bioanalyzer (Agilent Technol-
ogies, Palo Alto, USA). Microarray procedures were carried out
according to the manufacturer's protocols. Briefly, RNA was labeled
and hybridized with Cy3-dCTP, following the Agilent One-Color
Microarray-Based Gene Expression Analysis protocol (Agilent
Technology, V 6.5, 2010). The labeled cRNAs were then purified
by RNAeasy Mini Kit (Qiagen) and measured by NanoDrop ND-
1000 (NanoDrop, Wilmington, USA). Labeled cRNA was fragmen-
ted and hybridized to the Agilent SurePrint HD Zebrafish v3 GE
Figure 1. Generation of Irx1 knock-out zebrafish. Targeted gene mutation was performed by TALEN and CRISPR/Cas9 knockout methods
for Irx1a (A) and for Irx1b gene (B), respectively. Frameshift mutation was caused by the knockout strategies. Insertion or deletion of the
nucleotides was indicated by red letterings. (C) Three-day-old embryos of the zebrafish mutants. While either Irx1a or Irx1b homozygote
mutants did not show abnormal morphology during embryonic development, some siblings (homozygote for both Irx1a and Irx1b) from
the breeding of Irx1a−/−/1b+/− and Irx1a+/−/1b−/− showed severe morphologic abnormality. This suggests that majority of homozygote
mutants of Irx1a and Irx1b are developmentally defective. A few of Irx1a−/−/1b−/− zebrafish, however, were found to survive up to
3 months of age but were not fertile and died within 6 months of age.
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17 hours at 65°C in an Agilent hybridization oven and washed at
room temperature according to the Agilent One-Color Microarray-
Based Gene Expression Analysis protocol (Agilent Technology, V 6.5,
2010). The hybridized array was immediately scanned with an
Agilent Microarray Scanner D (Agilent Technologies, Inc.), and
expression data were generated using Agilent Feature Extractionsoftware v11.0 (Agilent Technologies). Gene-Enrichment and
Functional Annotation analysis for significant probe list was
performed using Gene Ontology (www.geneontology.org/). All data
analyses and visualization of differentially expressed genes were
conducted by using R 3.1.2 (www.r-project.org). Hierarchical
clustering analysis based on Euclidean distance, and average linkage
was performed using TMEV software [24].
Figure 2. Expression of zebrafish Irx1 gene. (A) Whole mount ISH expression in embryogenic zebrafish. Irx1 gene expression is found
highly in brain area at early developmental stage (see 48 hpf, hours postfertilizaton) and later distributed to internal organs (5 dpf, days
postfertilization). (B-D) Images of ISH in 3-month-old adult tissue sections. (B) Expression in intestine and kidney. Both Irx1a and Irx1b
genes are expressed at the crypt base of intestines and renal tubular cells. (C) ISH observation of Irx1 gene expression in reproductive
organs, typically in primordial germ cells and oocytes (insets indicate 40× low-power images). (D) Expression in the liver and bile ducts.
While none of the hepatocytes express Irx1 gene, meticulous examination revealed obvious expression in the biliary tree including
extrahepatic (arrows) and intrahepatic bile ducts (arrowheads).
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Real-time PCR was performed by using the whole zebrafish embryos
and 3-month-old zebrafish liver and intestine. RNA was extracted by
using TRIzol reagent (Invitrogen), and cDNA was synthesized from
2 μg of the total RNA with a Maxima First Stand cDNA Synthesis Kit
(Thermo Fisher Scientific, K1641, Glen Burnic, MD). The real-time
PCR was conducted by using Maxima SYBR Green/ROX qPCR
Master Mix (Thermo Fisher Scientific, K0222) on a 7300 Real-Time
PCR System (Applied Biosystems, Foster city CA). The primer
sequences for Real-time PCR are shown in Supplementary Table1.
For Western blot analyses, whole cell protein extracts were
prepared with a lysis buffer (50 mM Tris–HCL (pH 7.9), 100 mM
NaCl, 1 mM EDTA, 2% SDS, 0.1 mM EDTA, 0.1 mM EGTA,
0.1 M and protease and phosphatase inhibitor cocktail (Thermo
scientific)). After treating 20 μg of the total protein with Laemmlisample buffer and heating at 100°C for 5 minutes, the total proteins
were resolved by 8% and 12% SDS-polyacrylamide gel electropho-
resis (PAGE). The electroblotted nitrocellulose membrane (GE
Healthcare life Sciences) containing the proteins was blocked in a
solution with 5% nonfat dry milk and PBS-T. Antibodies used for
Western blot analyses were rabbit anti–cyclin D1 (1:1000, Abcam,
EPR2241), rabbit anti–cyclin E1 (1:1000, Abcam, EP435E), mouse
anti–cyclin B1 (1:1000, Santacruz, GNS1), mouse anti–cyclin A
(1:1000, Santacruz, B-8), anti–human IRX1 (1:500, Abcam,
ab66310), mouse anti-turboGFP (1:1000, Origene, TA150041),
and β-actin (1:2000, Cell signaling, #4967 L). Visualization of the
protein band was done with peroxidase-conjugated secondary
antibody (1:5000, Gendepot, USA), and the band density was
measured by using TINA image software (Raytest, Straubenhardt,
Germany).
Figure 3. Abnormal phenotypes developed in multiple organs caused by Irx1 knockout in zebrafish (long-term observation up to
18 months). (A, B, and E) Control. (C and D, F-L) Irx1a knockout (Irx1b data not shown due to similar images). Hyperplasia or tumor
developed in the multiple organs where certain degree of Irx1 expression was noted on the ISH experiment. Note the testicular (black
arrowheads), renal (red arrowheads), and ovarian tumors (arrow). (L) Cystic tumor of ovary (Inset indicates IHC image of CK19).
Neoplasia Vol. 21, No. 10, 2019 IRX1 Suppresses Tumorigenesis by Regulating Cell Cycle Jung et al. 1007Histology and Immunohistochemistry (IHC) and In Situ
Hybridization
Histologic evaluation was done by using 4-μm sections of
paraformaldehyde-fixed and paraffin-embedded tissue. Hematoxy-
lin/eosin (H&E) staining was performed according to standard
protocols. IHC and ISH experiments were carried out as previously
described [22,25]. Primary antibodies used for IHC were mouse anti–
proliferating cell nuclear antigen (PCNA, 1:2000), mouse anti–-
cytokeratin 19 (CK19, 1:500), and mouse anti-pancytokeratin
(1:500) purchased from Abcam (Cambridge, MA). For ISH,
riboprobes were generated by PCR amplification with partial
cDNA using appropriate primers. Primer sequences used for PCR
were 5′-ATGTCTTTCCCCCAGCTGGG-3′ (forward) and 5′-
CTAATACGACTCACTATAGGGCTCCAGATCTAT
CTCCTCTTCG-3′ (reverse) for Irx1a (product size 633 bp), and
5′-ATGTCGTTCCCCCAACTGGG-3′ (forward) and 5′-CTAA
TACGACTCACTATAGGGCCATATCGATGGTCTCCA
GATC-3′ (reverse) for Irx1b (product size 658 bp). The underlined
sequences are T7 RNA polymerase-binding sites. In vitro transcription
was carried out using mMEssagemMACHINET7 ultra Kit (Ambion).
Hybridization was done at 60°C for overnight, and serial stringent wash
was done at 68°C. Hybridized riboprobe was detected by anti-dig
antibody binding and detected by NBT/BCIP AP substrate solution
(Roche). The slides were counterstained with neutral red.Overexpression of IRX1 Gene in Human Cancer Cells and Cell
Cycle Analysis
IRX1 gene overexpression was made to the human cholangiocar-
cinoma cell lines HuCCT1 and SNU1196. These cells werelentivirally transformed with the human IRX1 gene fused with
IRX1-GFP (pLentiCMV:Irx1-GFP, Origene, RG218767) or GFP
(pLentiCMV:GFP, Origene, PS100019) alone as a control. After the
lentiviral transduction, GFP-positive cells were selected by using BD
Aria III FACS (Becton Dickinson Co.). Phenotypic changes in the
cell proliferation and apoptosis were then evaluated.
For cell cycle analysis by flow cytometry, the transduced
cholangiocarcinoma cells were fixed with ethanol, labeled with
mitotic marker (Alexa588-conjugated anti–phosphohistone H3, Cell
Signaling 3458S), and stained with propidium iodide. To evaluate the
cell cycle progression, the transduced cells were synchronized at either
G1/S phase or G2/M phase by treating with hydroxyurea (1 mM,
Sigma H8627) or nocodazole (100 ng/mL, Sigma, M1404),
respectively. After 16 hours of cell cycle arrest, the synchronized
cells were released from the cell cycle arrest, harvested at indicated
time point, and then processed to flow cytometry experiment.
Annexin V antibody (Santacruz, sc-74,438) was used to perform
apoptotic analysis.Results
Targeted Knockout and Expression of Irx1 Gene in Zebrafish
In order to obtain knockout mutants of target genes, each gene was
separately designed to induce frameshift mutation by using TALEN
and CRISPR/Cas9 technologies for Irx1a and Irx1b, respectively
(Figure 1). DNA break at the identified targeted site was induced by
injecting the capped mRNA into the yolk of AB zebrafish embryos
(See Materials and Method). Genomic DNA sequencing of the
Figure 4. Bile duct phenotypes and tumor invasions found in the Irx1a knockout (Irx1b data not shown due to similar images). (A and B) A
large liver mass (boundary by red arrowheads) showing positivity for PCNA. The tumors often invaded the liver (C and K), intestine (E), and
pancreas (D, G, and L). The bile duct tumor was often multifocal (H and I) (black arrowheads). (M) Tumor cells revealed robust expression
of PCNA suggesting enhanced proliferation. (N) IHC for pancytokeratin in tumor cells. (O and P) ISH images for Irx1 mRNA showing
positive expression of both Irx1a and Irx1b genes in the tumor cells. As the bile duct cells in the knockout lines also produce Irx1 mRNAs
that harbor mutations, the positivity on ISH is supportive finding that the tumors are originated from bile duct cells. P, pancreas; L, liver.
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insertion and two nucleotides (CG) deletion with three nucleotides
insertion (TTT) occurred, respectively, in the Irx1a and Irx1b regions,
resulting in frameshift mutation (Figure 1, A and B). Homozygous
mutants of Irx1a and Irx1b were then successfully generated (Figure 1C).
The homozygous mutants for Irx1a (Irx1a−/−) and Irx1b (Irx1b−/−) were
vital without showing morphological abnormality at embryogenic stageTable 1. Phenotypic Changes Induced by Irx1 Gene Knockout
6 Months 12 M
Irx1a −/− Irx1b −/− Irx1a
Intestinal hyperplasia 8.3% (2/24) 4.2% (1/24) 37.5%
Testicular hyperplasia 0% (0/13) 0% (0/12) 25.0%
Testicular tumor 0% (0/13) 0% (0/12) 8.3%
Ovarian hyperplasia 0% (0/11) 0% (0/12) 8.3%
Ovarian tumor 0% (0/11) 0% (0/12) 8.3%
Renal hyperplasia 8.3% (2/24) 4.2% (1/24) 20.8%
Renal tumor 0% (0/24) 0% (0/24) 0% (0
Bile duct hyperplasia 50.0% (12/24) 25.0% (6/24) 70.8%
Bile duct tumor 25.0% (6/24) 4.2% (1/24) 45.8%and survived long enough to cause abnormal phenotypes later. However,
homozygous mutants for both Irx1a and Irx1b (Irx1a−/−/b−/−) were
severely malformed (Figure 1C). Only few of them survived till 3 months
of age (all died within 6 months) and were not fertile, reflecting the lethal
phenotype found in other mammal study.
We also performed expression analysis of the Irx1 gene in zebrafish
(Figure 2). In humans, the IRX1 gene is expressed in multiple organsonths 18 Months
−/− Irx1b −/− Irx1a −/− Irx1b −/−
(9/24) 25.0% (6/24) 54.2% (13/24) 33.3% (8/24)
(3/12) 8.3% (1/12) 54.5% (6/11) 18.2% (6/11)
(1/12) 0% (0/12) 9.1% (1/11) 0% (0/11)
(1/12) 8.3% (1/12) 30.8% (4/13) 15.4% (2/13)
(1/12) 0% (0/12) 7.7% (1/13) 7.7% (1/13)
(5/24) 12.5% (3/24) 37.5% (9/24) 16.7% (4/24)
/24) 0% (0/24) 4.2% (1/24) 0% (0/24)
(17/24) 37.5% (9/24) 87.5% (21/24) 66.7% (16/24)
(11/24) 12.5% (3/24) 66.7% (16/24) 50.0% (12/24)
Figure 5. cRNA microarray analysis. (A and B) Differential genes were explored by microarray (Agilent Gene Chip) analysis using the
visceral organs of 3-month-old zebrafish from AB, Irx1a−/−, and Irx1a−/−/b−/−. The microarray revealed 687 upregulated and 963
downregulated genes by Irx1a/b knockout. Significant canonical pathways were cyclins and cell cycle regulation, mitotic roles of polo-like
kinase, FXR/RXR activation, estrogen-mediated S-phase entry, and cell cycle control of chromosomal replication. The upper colored bar
indicates the gene expression, and the metric used was Euclidean distance, with average linkage for distance between clusters. (C) Real-
time RT-PCR recapitulated the microarray results.
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reproductive organ [1–14]. Similarly, our whole mount ISH experiment
showed that zebrafish embryo also expressed the gene in the various organs
(Figure 2A). ISH experiment with different organ tissue sections further
revealed the detailed expression patterns in those organs (Figure 2, B and
C). Meticulous examination of the ISH slides under a microscope showed
that the gene was also expressed in both intrahepatic and extrahepatic bile
ducts, which was not previously documented (Figure 2D).Tumorigenesis Occurs in Multiple Organs of the Irx1 Gene
Knockout Zebrafish
Observation of the abnormal phenotypes caused by the Irx1 gene
knockout was done with the homozygous Irx1a-null and Irx1b-null
zebrafish. In order to do this, serial analysis of histology was carried
out with the tissue sections from 3-, 6-, 12-, and 18-month-old
knockout zebrafish (Figures 3 and 4). The result showed that
hyperplasia and/or tumor developed in the multiple organs where we
1010 IRX1 Suppresses Tumorigenesis by Regulating Cell Cycle Jung et al. Neoplasia Vol. 21, No. 10, 2019
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was successfully made to the targeted organs and that the Irx1 gene
was involved in tumor suppression in zebrafish (Figure 3). During our
observation of the tumor formation among the different organs, we
found that the hyperplasia and tumorigenesis occurred more
frequently in bile duct organ than occurred in any other organs
(Figure 4, Table 1). Biliary hyperplasia occurred as early as 3 months
old in the knockout zebrafish, and the bile duct tumors showed
occasionally invasive growth into the liver (Figure 4C), pancreas
(Figure 4, D and G), and intestine (Figure 4E). ISH for Irx1 revealed
rather strong expression of both Irx1a and Irx1b mRNA (although the
mRNA harbors mutations) in the tumor cells (Figure 4,O and P). This
seemed to be caused by loss of feedback mechanism of transcriptional
inhibition due to lack of functioning Irx1 protein. As the normal bile
duct cells express Irx1 mRNAs (Figure 2D), the positivity on ISH is
supportive finding that the tumors are originated from bile duct cells.
Interestingly, although the abnormal phenotypes were observed
basically to be identical in both Irx1a and Irx1b knockout mutants,
we found that the abnormal phenotypes were prominently induced by
Irx1a gene knockout than induced by Irx1b gene knockout (Table 1).
This suggests that functional preservation of the gene relies more on
Irx1a gene. During investigation of other organs, organomegaly by
hyperplasia was a prominent feature with occasional tumor formation in
testis, ovary, and kidney. Taken together, the results suggest that the
gene acts as antitumorigenesis in zebrafish.
Differential Gene Expression Induced by Irx1 in Zebrafish
We further characterized the relevant phenotypes and possible
mechanism of the antitumorigenesis driven by the Irx1. To do this,
we performed microarray (Agilent Gene Chip) analysis using the
cRNA from the visceral organs of 3-month-old zebrafish (Figure 5):
Experimental samples were one pooled AB control, two pooled Irx1a−/−,
and two separately prepared Irx1a−/−/b−/− zebrafish RNAs. Because
majority of the homozygote mutants of both Irx1 genes did not survive,
repetitive genotyping was required to find Irx1a−/−/b−/−. The result
indicated that among the 80 adult zebrafish bred from the crossing of
Irx1a+/−/b−/− and Irx1a−/−/b+/, only four of them were found to be
Irx1a−/−/b−/−. Based on the microarray analysis, we were able to find
687 upregulated and 963 downregulated genes in the knockout mutant
(Figure 5, A and B, refer to Supplementary Fig. 1 for high-resolution
image). Of them, five top canonical pathways changed by Irx1
knockout were found to include cyclins and cell cycle regulation,
mitotic roles of polo-like kinase, farnesoid X / retinoid X receptor (FXR/
RXR) activation, estrogen-mediated S-phase entry, and cell cycle
control of chromosomal replication (Supplementary Table 2). Further
categorizing them into detailed manner according to Gene Ontology
(GO) terms, we found that the largest number of the differential genes
was involved in cell cycle (165 genes for cyclins and cell cycle regulation,
mitotic roles of polo-like kinase, and cell cycle; 137 genes for cell death
and survival; 115 for cell growth and proliferation; and 101 for cancer
pathways). The result suggests that cell cycle pathways are possiblyFigure 6. Transduction of human IRX1 gene into human cholangi
expression in four different cholangiocarcinoma cell lines. Among the
expression cell line) were selected for overexpression study. (B) Lent
localization of IRX1-GFP in Irx1 transduced cells whereas GFP-alone t
experiment confirmed the transduced protein, tGFP. Fused IRX1-tGFP
The results showed that IRX1 overexpression resulted in decreased ce
cytometry analysis for cell death induced by H2O2 treatment showing
cytometry for cell cycle change. IRX1-expressing cells showed decreregulated by IRX1 (list of differential genes relevant to cell cycle is
shown in Supplementary Table 3). To further confirm this, real-time
RT-PCR was performed against the genes related to cell cycle
regulation, and we found that the results were largely correlated with
the microarray data (Figure 5C, refer to Supplementary Table 1 for
primer sequences). Taken together, our result suggests that the
significant canonical pathway of IRX1 in achieving antitumorigenesis
is done by regulating cell cycle.
Overexpression of IRX1 Gene Inhibits Proliferation of Human
Cholangiocarcinoma Cells
As the tumorigenesis in bile duct was found to be the predominant
phenotype in the Irx1 knockout zebrafish (Figure 4), we decided to
further evaluate the role of Irx1 by performing transduction of human
IRX1 gene into cholangiocarcinoma cell lines. To do this, two
different cholangiocarcinoma cell lines, HuCCT1 and SNU1196,
respectively, containing high and low IRX1 gene expression, were
chosen for the transduction study. In this way, we expected that
phenotypic changes induced by IRX1 gene overexpression would be
more evidently appeared on SNU1196, the low IRX1 gene expressing
cell line, than appeared on the high IRX1 gene expressing cell line
HuCCT1. GFP gene was fused to the IRX1 gene to enable
observation of the transgene expression (Figure 6, A and C). The
result showed that overexpression of the IRX1 gene resulted in
decreased cell proliferation of both HuCCT1 and SNU1196,
supporting our finding that the gene is involved in antitumorigenesis
(Figure 6D). Upon treatment with H2O2 to the cell lines, the
SNU1196 cells (the low Irx1 expressing cell) were found to be more
sensitive to oxidative stress, showing much more increased fraction of
Annexin V–positive (apoptotic) or propidium iodide–positive (dead)
cells in flow cytometry analysis (Figure 6E). The result suggested that
IRX1 gene expression inhibited cell proliferation and sensitized cells to
apoptotic stimuli. Furthermore, our flow cytometry experiment using
pHH3, a specific marker for mitosis, to examine the alteration of cell
cycle showed that IRX1 gene overexpression induced decrease of the
mitotic cell fraction in both HuCCT1 and SNU1196 (Figure 6F),
suggesting that Irx1 is associated with the cell cycle regulation.
Prominent Delay in Mitotic Progression of the IRX1
Overexpressed Cholangiocarcinoma Cells
To further confirm that the IRX1 is responsible for tumor
suppression by regulating cell cycle, the cholangiocarcinoma cells
were synchronized by treating the two different cell cycle blockers,
hydroxyuria and nocodazole, which block G1/S phase and G2/M
phase, respectively. The cells were then released and monitored for
exit from their arrested phases to find that IRX1 overexpression
actually delays the cell cycle. On flow cytometry analyses of the
released cells from their arrested point (i.e., 0 hour in the Figure 7, A
and B), the results showed that IRX1 expression actually delayed each
progression of the cell cycle in the two different cholangiocarcinoma
cell lines. The cell cycle delay was profoundly affected at mitotic exitocarcinoma cell lines. (A) Western blot experiment showed Irx1
se, HuCCT1 (high Irx1 expression cell line) and SNU1196 (low Irx1
iviral transduction of IRX1-GFP fusion gene (right). Note the nuclear
ransduced cell showed diffused expression (left). (C) Western blot
protein bands are seen with larger size. (D) Cell proliferation assay.
llular proliferation in both HuCCT1 and SNU1196 cell lines. (E) Flow
increased susceptibility to H2O2 in the Irx1-expressing cells. (F) Flow
ased mitotic fraction measured by phosphohistone H3 (pHH3).
Figure 7. Cell cycle synchronization study. (A and B) Cell synchronization was obtained by treatment with hydroxyuria and nocodazole,
respectively, for G1/S and G2/M phase arrest. Arrest was then released, detecting the cell cycle progression. Dotted red lines indicate 2N
and 4N cells. The result showed that mitotic exit is markedly delayed by IRX1 overexpression, while S phase progression is slightly
delayed. Numbers in upper and lower lines indicate G1/S and G2/M fractions, respectively. (C) The mitosis marked by pHH3. G2/M phase-
blocked cells were released and stained for pHH3 at indicated time points. Yellow to white cells (red arrowheads) represent pHH3- and
GFP-positive cells. Numbers of percentage indicate fractions of the pHH3-positive cells. At 3 and 6 hours after release, higher cell
fractions are still positive for pHH3 in IRX1-expressing cells. (D) Western blot analysis against cyclins. The result showed that levels of
various cyclin expression are decreased by IRX1 expression.
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Confirmation of our observation was also done by pHH3 staining of
the released cells from nocodazole-induced M phase arrest. The result
showed that IRX1 overexpressing cells revealed higher fraction ofpHH3-positive cells at 3 and 6 hours after release, indicating that
delayed mitotic exit and reentry into G1 occurred in the transduced
cells (Figure 7C). Western blot experiments also detected decreased
amounts of active cyclins involved in cell cycle progression in those
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suggested that tumor suppression of the gene is mediated by
repressing cell cycle progression.
Discussion
IRX gene family encodes homeobox-containing transcription factors.
In mammalian, the genes are known to be clustered on two genomes
that consist of a total of six IRX genes, and the genes play important
roles in pattern formation during embryonic development [1–7]. All
IRX genes are found to be expressed either specifically or redundantly
in different organs. Among the IRX genes, recent studies showed that
IRX1 gene functions as a tumor suppressor [17]. Not only for the
tumor suppressor, IRX1 also acts an oncogene, especially when the
gene undergoes allelic deletion or promoter methylation. For
instance, in osteosarcoma, IRX1 was identified as a metastatic
oncogene that is activated by hypomethylation [26], whereas the gene
was reported as a tumor suppressor in other cancer types [14,15,18].
Although those reports suggest that IRX genes are involved in
regulation of tumor development, understanding of the mechanism
in tumorigenesis is very limited at current.
In zebrafish, Irx1 gene exists as a duplicated form, as Irx1a and
Irx1b genes. Identification and expression of the Irx1 gene in this
animal were first reported in 2001, but functional role of the gene was
unclear [27]. In fact, none of studies have revealed yet how the gene is
involved in antitumorigenesis. In this study of functional analysis of
Irx1 gene, we generated each of homozygous Irx1a and Irx1b
mutants that were vital and fertile to generate descendants (Figure 1).
To do this, we used two different knockout strategies, TALEN and
CRISPR/Cas9. At the beginning of this study, TALEN technology
was more accessible for us to generate knockout mutant, successfully
targeting Irx1a gene. This technology was however complicated and
inconvenient especially when generating constructs for knockout.
Thus, later, we used CRISPR/Cas9 technology for targeting Irx1b
gene. Homozygous Irx1a-null and Irx1b-null zebrafish were then
obtained from the F3 progenies produced by inbreeding of the F2
heterozygote progenies (Figure 1C).
Our investigation of the Irx1 gene expression showed that the gene
is expressed in various internal organs of zebrafish as similarly
displayed in other animals, including humans (Figure 2). Meticulous
expression study using ISH experiment included a prominent
expression of Irx1 gene also in bile duct which has never been
documented so far (Figure 2D). Observation of abnormal phenotypes
caused by the gene knockout in the zebrafish mutants revealed that
the mutants contained tumor development where the gene was
expressed (Figure 3). This suggests that the Irx1 gene is involved in
antitumorigenesis in multiple organs. In mammals, Irx genes often
showed overlapping patterns of expression, suggesting their redun-
dant roles in development [10]. From our investigation, we also
found that expression pattern of the two Irx1 genes was tissue and
organ specific but was redundant (Figure 2). The same redundancy
was phenotypically observed from both Irx1a and Irx1b knockout
mutants, although the abnormal phenotype was found to be more
prominent in the Irx1a mutant than appeared on Irx1b mutants. The
results suggested that the two genes were functionally overlapped and
that the functional preservation may dominantly rely on Irx1a gene.
Unlike in other mammalian studies with homozygous mutants, we
believe that because of this functional redundancy, the zebrafish
homozygous mutants were able to survive long enough to show the
phenotypic abnormality of tumorigenesis in the multiple organs,although the Irx1a/b knockout mutants did not survive longer than
6 months. Taken together, our observations revealed that Irx1 gene
functioned to suppress tumorigenesis in zebrafish at multiple
locations where the gene was expressed.
Further study with the zebrafish mutants was focused on
characterization of the gene behavior during the tumor development
especially in bile duct since the tumorigenicity in the particular organ
occurred more frequently than occurred in any other organs and the
bile duct tumor was often invasive to near organs, liver and pancreas
(Figure 4). Histological analysis with the serial sections obtained from
the internal organs well revealed how the tumor masses were severely
formed in the organs of the knockout mutants (Figure 3). This
finding also referred to our expression analysis, showing that the Irx1
gene was expressed in both intrahepatic and extrahepatic bile duct,
whereas the gene was not expressed in hepatocytes (Figure 2D). This
suggests that the gene may contain important roles in the
development of cholangiocarcinoma previously not known. As the
tumorigenicity in bile duct was found to be the predominant
phenotype in these Irx1 knockout zebrafish, we considered that study
with overexpression of IRX1 gene in human cholangiocarcinoma cell
lines was useful to confirm the IRX1 role in antitumorigenesis. In
vitro assay using the cholangiocarcinoma cell lines showed that
overexpression of the IRX1 gene resulted in decreased cell
proliferation and increased susceptibility to H2O2-induced oxidative
stress, supporting our finding that the gene is involved in
antitumorigenesis (Figure 6). Taken together, these results indicate
that IRX1 gene is a true tumor suppressor.
In an attempt of identifying the genes regulated by the
transcription factor Irx1 during antitumorigenesis, we performed
cRNA microarray assay using the cRNA obtained from the knockout
mutants (Figure 5). This microarray analysis allowed us to understand
changes of the downstream gene expression of Irx1. After
investigating 687 upregulated and 963 downregulated genes
identified from the microarray, our result showed that the significant
fold change of the genes fell into the category of the genes involved in
cell cycle regulation. Especially, we noticed that the highest fold
change occurred in CDKN2ab (homolog for CDKN2A in
mammals), a cyclin-dependent kinase inhibitor, which codes for
two proteins: p16INK4a and p14arf [28,29]. These two proteins are
known to act as tumor suppressor by regulating the cell cycle. The
result suggests that the significant canonical pathway of IRX1 in
antitumorigenesis is possibly done by regulating cell cycle. In a
previous study with gastric cancer, protein arginine methyltransferase
5 (PRMT5, an enzyme responsible for symmetric demethylation of
histone) has been introduced as an upstream regulator of IRX1,
suggesting that methylation of the gene is involved in tumorigenic
process [15]. Further study with PRMT5 has revealed that knockout
of IRX1 gene induces cell cycle arrest and growth inhibition [30].
Also, a study with head and neck squamous cell carcinoma has
suggested that methylation of IRX1 gene induces tumorigenesis by
causing decrease of the gene expression [18]. On the other hand,
overexpression of the IRX1 gene in this cancer cell has showed
suppression of the cell growth and colony formation. Taken together,
these results suggest that the IRX1 gene expression is suppressed by
hypermethylation during tumorigenesis and that restoring the gene
expression inhibits tumorigenesis in cancer cells. In our study with the
cholangiocarcinoma cell lines, IRX1 overexpression also resulted in
delayed progression of the tumor cell cycle along with decrease of
cyclin expression, and the most prominent changes were delayed
1014 IRX1 Suppresses Tumorigenesis by Regulating Cell Cycle Jung et al. Neoplasia Vol. 21, No. 10, 2019mitotic exit and reentry into G1 phase (Figure 7). Although it
necessitates to further clarify how IRX1 controls the progression of
mitotic phase, these results indicate that regulation of cell cycle is an
important mechanism of IRX1 function leading to tumor
suppression.
In this study with homozygous knockout mutants of Irx1 in
zebrafish, the results have demonstrated that the gene functions as a
true tumor suppressor. Our molecular study provides further
understanding of IRX1 gene function, revealing that tumor
suppression is mediated by repressing cell cycle progression. This
study also suggests potential roles of the gene in bile duct organ
previously undescribed. At the present study, however, we do not
understand how IRX1, as a transcription factor, regulates cyclin
production during cell cycle progression. Further molecular analysis is
needed to unveil the mechanism and the functional roles of IRX1 in
antitumorigenesis including cholangiocarcinoma.
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